A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam

Exclusion Criteria

• •1. Participants with a history of hypersensitivity to study drug(ZSP1273,warfarin, midazolam) or any component of study medication;
• •2. Participants with a history of and/or signs and symptoms of current abnormal hemostasis or blood dyscrasia or abnormal prothrombin time (PT), international normalized ratio (INR), or activated partial thromboplastin time at screening;
• •3. Smoking more than 5 cigarettes per day within 3 months prior to screening，or who cannot stop using any tobacco products during the study period;
• •4. Participants who donated blood/bleeding profusely (\> 400 mL) 3 months prior to randomization;
• •5. Those with clinically significant ECG abnormalities, or QTcF \> 450ms in men and QTcF \> 470ms in women;
• •6. Participants who test positive at screening for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody or Syphilis spirochete-specific antibodies (TPPA);
• •7. Participants who test positive at Screening and/or admission (Day -1) for alcohol abuse.
• •8. Females who are pregnant, lactating, or likely to become pregnant during the study.
• •9. History of dysphagia or any gastrointestinal disorder that affect absorption